[
  {
    "id": "TCGA-A2-A04Q-01Z-00-DX1.DF7ED6B6-7701-486D-9007-F26B6F0682C4-1",
    "image": "TCGA-BRCA/TCGA-A2-A04Q-01Z-00-DX1.DF7ED6B6-7701-486D-9007-F26B6F0682C4.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with infiltrating ductal carcinoma, poorly differentiated, TNM staging T1N0M0, with IHC results showing negative progesterone receptor, weakly positive HER2 (not amplified by FISH)?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Breast-conserving surgery (lumpectomy) or mastectomy, along with sentinel lymph node biopsy due to T1N0 staging. 2. Chemotherapy: Consider adjuvant chemotherapy based on the poorly differentiated grade and hormone receptor negativity. 3. Endocrine Therapy: Not applicable due to negative hormone receptor status. 4. Radiation Therapy: Adjuvant radiation therapy recommended if breast-conserving surgery is performed. 5. HER2-targeted Therapy: Not indicated as HER2 is not amplified by FISH."
      }
    ]
  },
  {
    "id": "TCGA-D9-A4Z3-01Z-00-DX1.DD40CC06-5F33-4C8D-BE76-80189D969EBE-1",
    "image": "TCGA-SKCM/TCGA-D9-A4Z3-01Z-00-DX1.DD40CC06-5F33-4C8D-BE76-80189D969EBE.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with malignant melanoma, nodular type, ulcerated, Clark level V, with a Breslow thickness of 75 mm, staging T4BM0N1B, and immunohistochemistry results showing HMB45 positive in few cells, MelanA negative, CKAE1/3 negative, and Ki67 at 50%?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Perform a wide local excision of the primary melanoma with appropriate margins to ensure complete removal of the tumor. 2. Lymph Node Management: Given the positive nodal involvement (N1b), perform a complete lymph node dissection of the affected nodal basin. 3. Adjuvant Therapy: Due to advanced staging and high-risk features, consider adjuvant immunotherapy with checkpoint inhibitors such as pembrolizumab or nivolumab. 4. Follow-up and Monitoring: Implement regular dermatological and oncological follow-ups with imaging studies and physical examinations to monitor for recurrence or metastasis."
      }
    ]
  },
  {
    "id": "TCGA-EE-A2M7-01Z-00-DX1.9BC4B066-11FD-4606-8D2D-66757BD5C0AD-1",
    "image": "TCGA-SKCM/TCGA-EE-A2M7-01Z-00-DX1.9BC4B066-11FD-4606-8D2D-66757BD5C0AD.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with metastatic malignant melanoma, staged as T3aM0N0, with immunohistochemistry results showing S100 positive and HMB45 negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Wide local excision of the primary tumor with sentinel lymph node biopsy to assess for any potential nodal involvement. 2. Adjuvant Therapy: Consider nivolumab or pembrolizumab, as these immune checkpoint inhibitors are recommended for patients with resected high-risk melanoma. 3. Regular Surveillance: Follow-up with regular physical examinations and imaging studies to monitor for recurrence or metastasis. Determine the frequency based on clinical guidelines and the patient's risk factors."
      }
    ]
  },
  {
    "id": "TCGA-ER-A1A1-06Z-00-DX1.CD88FBDD-AD5B-4063-8223-DDBA8A1F721B-1",
    "image": "TCGA-SKCM/TCGA-ER-A1A1-06Z-00-DX1.CD88FBDD-AD5B-4063-8223-DDBA8A1F721B.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with metastatic melanoma, staged as TXM0N3, with immunohistochemistry results showing Pankeratin cytokeratin negative, S100/S100a positive, and Melan-A focally positive?"
      },
      {
        "from": "gpt",
        "value": "1. Immunotherapy: Utilize immune checkpoint inhibitors, such as pembrolizumab or nivolumab, to enhance the body's immune response against melanoma cells. 2. Targeted Therapy: If the patient has a BRAF mutation, consider targeted therapies like dabrafenib combined with trametinib. 3. Radiation Therapy: Consider palliative radiation therapy to manage symptoms due to nodal involvement. 4. Clinical Trials: Evaluate the patient for eligibility in clinical trials, which may offer access to new therapies and combination treatments."
      }
    ]
  },
  {
    "id": "TCGA-FV-A2QR-01Z-00-DX1.2A2C52AC-8A5F-4E8E-95FE-C653D424FC21-1",
    "image": "TCGA-LIHC/TCGA-FV-A2QR-01Z-00-DX1.2A2C52AC-8A5F-4E8E-95FE-C653D424FC21.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with histologic grade I hepatocellular carcinoma, with TNM staging T1M0N0, and immunohistochemistry results showing CA19.9 negative, Pancytokeratin (AE1/AE3) negative, CK7 positive in two of three portions, CK20 predominantly positive, HepPar-1 positive in small numbers of tumor cells, CK8/18 (CAMS.2) strongly positive, vimentin present in some tumor cells, and Alpha-1 antitrypsin (Alpha1-AT) strongly positive in all tumor cells?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Consider partial hepatectomy or liver resection given the T1 stage, which indicates a single tumor without vascular invasion. This is appropriate for early-stage hepatocellular carcinoma. 2. Ablation Therapy: If surgery is not feasible due to patient health or liver function, consider local ablation techniques such as radiofrequency ablation (RFA) or microwave ablation (MWA) to target and destroy the tumor. 3. Liver Transplantation: Evaluate for liver transplantation, especially if the patient's liver function is compromised, as this can potentially cure both the cancer and the underlying liver disease. 4. Surveillance: Post-treatment, implement regular surveillance with imaging and alpha-fetoprotein (AFP) monitoring to detect any recurrence early."
      }
    ]
  },
  {
    "id": "TCGA-MQ-A6BN-01Z-00-DX1.6DA0AD03-A9F5-4F77-B9F6-C5CD4904975B-1",
    "image": "TCGA-MESO/TCGA-MQ-A6BN-01Z-00-DX1.6DA0AD03-A9F5-4F77-B9F6-C5CD4904975B.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with malignant epithelioid mesothelioma, staged as T2MXN1, with immunohistochemistry results showing diffuse positivity for Cytokeratin (AE1/AE3) and CKS/6, focal positivity for Calretinin and WT1, and negative results for mCEA, Ber-P4 (rare cells positive), and TTF1?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Evaluate for potential pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP), considering the patient's overall health, tumor resectability, and nodal involvement. 2. Chemotherapy: Administer a combination of pemetrexed and cisplatin, standard for malignant mesothelioma, to reduce tumor burden and improve survival rates. 3. Radiation Therapy: Consider adjuvant radiation therapy post-surgery for local control, targeting residual tumor cells to minimize recurrence risk."
      }
    ]
  },
  {
    "id": "TCGA-A2-A0EU-01Z-00-DX1.13335BEB-63D4-469B-A389-8A079A096129-1",
    "image": "TCGA-BRCA/TCGA-A2-A0EU-01Z-00-DX1.13335BEB-63D4-469B-A389-8A079A096129.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with multifocal infiltrating ductal carcinoma, Nottingham grade 3, TNM staging T1cN0M0, being ER-positive, PR-positive, and HER2-negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Breast-conserving surgery (lumpectomy) or mastectomy, depending on tumor size, breast size, and patient preference. Consider sentinel lymph node biopsy. 2. Chemotherapy: Adjuvant chemotherapy may be considered due to the high-grade nature of the tumor. 3. Endocrine Therapy: Tamoxifen or aromatase inhibitors for at least 5 years due to strong ER and PR positivity. 4. Radiation Therapy: Adjuvant radiation therapy is recommended, especially if breast-conserving surgery is performed."
      }
    ]
  },
  {
    "id": "TCGA-E2-A1LE-01Z-00-DX1.22856B2A-FBAA-4530-AEEC-E8F77BDA7F7F-1",
    "image": "TCGA-BRCA/TCGA-E2-A1LE-01Z-00-DX1.22856B2A-FBAA-4530-AEEC-E8F77BDA7F7F.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with multifocal invasive ductal carcinoma, SBR Grade 3, TNM staging T2N3M0, with ER-negative, PR-negative, and HER2-positive IHC results?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Mastectomy is recommended due to multifocality, along with axillary lymph node dissection due to extensive nodal involvement (N3). 2. Chemotherapy: Neoadjuvant or adjuvant chemotherapy should be administered before or after surgery, respectively, given the high grade and nodal status. 3. HER2-targeted Therapy: Include trastuzumab (Herceptin) with chemotherapy and continue for 1 year as maintenance therapy due to HER2 positivity. 4. Radiation Therapy: Post-mastectomy radiation therapy is advised to address the extensive nodal involvement and ensure local control."
      }
    ]
  },
  {
    "id": "TCGA-GF-A3OT-01Z-00-DX1.014B8884-EE9D-4F3A-81BB-9DCAC92CC2AE-1",
    "image": "TCGA-SKCM/TCGA-GF-A3OT-01Z-00-DX1.014B8884-EE9D-4F3A-81BB-9DCAC92CC2AE.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with metastatic melanoma, staged as T3N3M0, with immunohistochemistry results showing positive S100, melanA, HMB45, and tyrosinase; negative IgG, IgA, C3, and fibrinogen; and 1+ granular staining for IgM along the basement membrane zone?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: As the melanoma is metastatic to lymph nodes (N3), consider complete lymph node dissection if resectable. Evaluate any primary or symptomatic secondary sites for surgical resection. 2. Immunotherapy: Initiate immune checkpoint inhibitors, such as pembrolizumab (Keytruda) or nivolumab (Opdivo), as these are strongly recommended for metastatic melanoma. 3. Targeted Therapy: If specific mutations (e.g., BRAF V600) are present, consider targeted therapies such as dabrafenib and trametinib. 4. Radiation Therapy: Use radiation therapy for local control of nodal disease or symptomatic metastases. 5. Clinical Trials: Enroll in clinical trials if available, as novel therapies may provide additional benefit.  This comprehensive approach addresses both local and systemic disease control."
      }
    ]
  },
  {
    "id": "TCGA-DD-A3A6-01Z-00-DX1.FCF4A7E7-A0F9-4B5D-B751-D990703EA261-1",
    "image": "TCGA-LIHC/TCGA-DD-A3A6-01Z-00-DX1.FCF4A7E7-A0F9-4B5D-B751-D990703EA261.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with Grade 2 hepatocellular carcinoma, TNM staging T2N0M0, with immunohistochemistry results showing CAM 5.2 positive, Vimentin positive, Alpha fetoprotein positive, p-CEA negative, S-100 negative, Actin negative, Albumin mRNA weakly positive, and HMB-45 positive?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment:     - Surgical resection is recommended if the patient has good liver function and the tumor is resectable.    - Liver transplantation may be considered if the patient meets criteria for transplantation and there is more extensive liver disease.  2. Locoregional Therapies:    - Transarterial chemoembolization (TACE) can be considered for patients who are not candidates for surgical resection.    - Radiofrequency ablation (RFA) might be an option for smaller tumors, particularly if surgery is not feasible.  3. Systemic Therapy:    - Sorafenib, a targeted therapy, is recommended if the disease progresses or if locoregional therapies are not suitable. Other systemic treatments include lenvatinib or other approved tyrosine kinase inhibitors.  4. Monitoring and Follow-Up:    - Regular imaging and alpha-fetoprotein (AFP) level monitoring to assess treatment efficacy and detect recurrence.  5. Supportive Care:    - Address liver function support and manage any complications arising from cirrhosis or liver dysfunction."
      }
    ]
  },
  {
    "id": "TCGA-EM-A3O3-01Z-00-DX1.F1D69AEB-CBBD-49EE-A2F4-411A11E3B3AC-1",
    "image": "TCGA-THCA/TCGA-EM-A3O3-01Z-00-DX1.F1D69AEB-CBBD-49EE-A2F4-411A11E3B3AC.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with widely invasive papillary thyroid carcinoma, staged as T2MXN1A, with immunohistochemistry results showing thyroglobulin positive, TTF-1 positive, HBME-1 positive (apical and membranous), vimentin positive, monoclonal CEA positive (focal), CD31 negative, CD5 negative, calcitonin negative, and p53 with less than 3% of tumor cell nuclei?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform a total thyroidectomy to remove the primary thyroid tumor and any involved lymph nodes, especially since there is nodal involvement (N1A).  2. Lymph Node Dissection: Central neck dissection to remove metastatic lymph nodes.  3. Radioactive Iodine Therapy: Post-surgical I-131 ablation to target residual thyroid tissue and metastatic disease, due to positive thyroglobulin and extensive invasion.  4. Thyroid Hormone Therapy: Administer levothyroxine to suppress TSH, reducing the risk of tumor recurrence.  5. External Beam Radiation Therapy: Consider for patients with incomplete resection or extranodal extension, considering the extensive invasion.  6. Long-term Follow-up: Regular follow-up with serum thyroglobulin levels and neck ultrasound to monitor for recurrence or metastasis."
      }
    ]
  },
  {
    "id": "TCGA-ZM-AA0E-01Z-00-DX1.D673EF20-56BB-4CBB-96E7-CDE7E38058BF-1",
    "image": "TCGA-TGCT/TCGA-ZM-AA0E-01Z-00-DX1.D673EF20-56BB-4CBB-96E7-CDE7E38058BF.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with seminoma, with TNM staging T1M0NX, and immunohistochemistry results showing CD117 positive and partially PLAP positive?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform an orchiectomy to remove the affected testicle, which is the primary treatment for seminoma. 2. Surveillance: Due to the T1 stage and absence of metastasis (M0), consider active surveillance post-orchiectomy, with regular follow-ups including physical exams, tumor marker tests, and imaging. 3. Radiation Therapy: Alternatively, if surveillance is not preferred or there are high-risk features, offer adjuvant radiation therapy to the para-aortic lymph nodes to reduce the risk of recurrence. 4. Chemotherapy: In certain cases, adjuvant single-agent carboplatin may be offered as an alternative to radiation, especially if the patient prefers to avoid radiation therapy or has contraindications for it."
      }
    ]
  },
  {
    "id": "TCGA-DA-A1I1-01Z-00-DX1.08A88C76-48C4-4724-AF64-24F99B7D33AD-1",
    "image": "TCGA-SKCM/TCGA-DA-A1I1-01Z-00-DX1.08A88C76-48C4-4724-AF64-24F99B7D33AD.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with metastatic malignant melanoma, staged as T0N2aM0, with immunohistochemistry results showing S100 positive and Melan-A positive?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Given the N2a stage (clinically occult nodal metastasis), perform a complete lymph node dissection to remove affected lymph nodes. 2. Systemic Therapy: Administer adjuvant systemic therapies:     - Immune Checkpoint Inhibitors: Consider using pembrolizumab or nivolumab to help boost the immune response against melanoma cells.     - Targeted Therapy: If mutations like BRAF V600E/K are present, use targeted therapies such as dabrafenib combined with trametinib. 3. Radiation Therapy: Assess for possible adjuvant radiation therapy, particularly if the risk of recurrence in the node basin is high or if complete surgical resection isn't possible. 4. Regular Monitoring: Implement a schedule for regular follow-up visits with imaging and physical exams to monitor for any signs of recurrence or metastasis."
      }
    ]
  },
  {
    "id": "TCGA-AO-A0J6-01Z-00-DX1.D0C003CE-E112-4375-953D-78404C9D62DA-1",
    "image": "TCGA-BRCA/TCGA-AO-A0J6-01Z-00-DX1.D0C003CE-E112-4375-953D-78404C9D62DA.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with ER-positive, PR-positive, HER2-negative invasive ductal carcinoma, Nottingham grade 3, with TNM staging T2N0M0?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Consider breast-conserving surgery (lumpectomy) or mastectomy, depending on the tumor size and patient preference. Sentinel lymph node biopsy is also recommended. 2. Chemotherapy: Adjuvant chemotherapy should be considered due to the high grade of the tumor (grade 3). 3. Endocrine Therapy: Administer tamoxifen or an aromatase inhibitor for at least 5 years based on the ER/PR positivity. 4. Radiation Therapy: Recommend adjuvant radiation therapy if breast-conserving surgery is chosen to reduce local recurrence risk."
      }
    ]
  },
  {
    "id": "TCGA-55-8513-01Z-00-DX1.E21776FE-DF49-48D1-90D6-6F71D0764492-1",
    "image": "TCGA-LUAD/TCGA-55-8513-01Z-00-DX1.E21776FE-DF49-48D1-90D6-6F71D0764492.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with well-differentiated invasive mucinous adenocarcinoma, staged as T3MXN0, with immunohistochemistry results showing CK7 positive, CK20 negative, CDX2 negative, Villin negative, Napsin-A weak positive, and TTF-1 negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Primary treatment should involve a lobectomy or pneumonectomy, depending on the tumor's location and size, with lymph node sampling or dissection to accurately determine nodal involvement. 2. Chemotherapy: Consider adjuvant chemotherapy post-surgery with agents such as cisplatin and pemetrexed, especially due to the T3 staging, to reduce the risk of recurrence. 3. Radiation Therapy: Evaluate the potential benefit of adjuvant radiation therapy if margins are close or positive post-surgery to target any residual tumor cells. 4. Follow-Up and Monitoring: Regular follow-up with imaging and clinical evaluations to monitor for recurrence or progression, given the MX staging indicating unknown metastasis status."
      }
    ]
  },
  {
    "id": "TCGA-E2-A10A-01Z-00-DX1.98B19EF1-0DAE-4DC6-8B0E-963CFABC6724-1",
    "image": "TCGA-BRCA/TCGA-E2-A10A-01Z-00-DX1.98B19EF1-0DAE-4DC6-8B0E-963CFABC6724.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with multifocal invasive ductal carcinoma, SBR Grade II, with TNM staging M0T3N0 (I-) and IHC results showing ER-positive, PR-positive, and HER2-negative status?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Consider mastectomy or breast-conserving surgery based on multifocal presentation and patient preference, followed by sentinel lymph node biopsy. 2. Endocrine Therapy: Tamoxifen or aromatase inhibitors for at least 5 years, given the positive ER and PR status. 3. Radiation Therapy: Adjuvant radiation therapy is recommended, especially if breast-conserving surgery is chosen. 4. Chemotherapy: Generally not recommended due to absence of nodal involvement and HER2 negativity, but may be considered based on patient-specific factors such as tumor size and grade."
      }
    ]
  },
  {
    "id": "TCGA-GM-A2DB-01Z-00-DX1.9EE36AA6-2594-44C7-B05C-91A0AEC7E511-1",
    "image": "TCGA-BRCA/TCGA-GM-A2DB-01Z-00-DX1.9EE36AA6-2594-44C7-B05C-91A0AEC7E511.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with triple-negative invasive ductal carcinoma, TNM staging T2N0M0?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform breast-conserving surgery or mastectomy, based on the size of the tumor and patient preference, followed by sentinel lymph node biopsy. 2. Chemotherapy: Administer adjuvant chemotherapy, given the triple-negative status and the tumor size. 3. Radiation Therapy: Consider post-surgical radiation therapy, particularly if breast-conserving surgery was performed."
      }
    ]
  },
  {
    "id": "TCGA-BH-A0WA-01Z-00-DX1.C0EB7B73-5529-49EC-B660-3F849B041963-1",
    "image": "TCGA-BRCA/TCGA-BH-A0WA-01Z-00-DX1.C0EB7B73-5529-49EC-B660-3F849B041963.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with metaplastic infiltrating ductal carcinoma, Grade 3, TNM staging T1N0M0, with triple-negative hormone receptor status and HER2 1+?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform a wide local excision or mastectomy based on tumor size and location, combined with sentinel lymph node biopsy to confirm node-negative status. 2. Chemotherapy: Administer adjuvant chemotherapy due to high-grade histology and triple-negative status, typically involving anthracycline and taxane-based regimens for patients with early-stage disease. 3. Follow-up: Provide regular follow-ups with imaging and clinical examination to detect any recurrence or metastasis early."
      }
    ]
  },
  {
    "id": "TCGA-EE-A2GI-01Z-00-DX1.3555691F-4DCF-45E9-9360-A7F34361B7AA-1",
    "image": "TCGA-SKCM/TCGA-EE-A2GI-01Z-00-DX1.3555691F-4DCF-45E9-9360-A7F34361B7AA.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with metastatic melanoma, TNM staging T1AM0N0, with immunohistochemistry results showing S100 positive, HMB45 positive, Melan A positive, no aberrant expression of CD20/CD79/CD43 by B-lymphocytes, and Cyclin D1 negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Wide local excision of the primary tumor with appropriate surgical margins is recommended, even for early-stage lesions like T1A. 2. Adjuvant Therapy: Given the metastatic potential despite the current staging, consider close monitoring and follow-up. Adjuvant therapy may not be immediately necessary if the patient is entirely resected and has no high-risk features. 3. Immune Checkpoint Inhibitors: If metastasis is detected during follow-ups, treatment with immune checkpoint inhibitors such as pembrolizumab or nivolumab could be considered. 4. Targeted Therapy: In case of BRAF V600 mutation positivity, targeted therapy with BRAF inhibitors (e.g., vemurafenib) combined with MEK inhibitors (e.g., cobimetinib) may be appropriate."
      }
    ]
  },
  {
    "id": "TCGA-D3-A1Q1-06Z-00-DX1.7E87AE47-8145-464D-AFBC-82DEAC42F492-1",
    "image": "TCGA-SKCM/TCGA-D3-A1Q1-06Z-00-DX1.7E87AE47-8145-464D-AFBC-82DEAC42F492.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with metastatic malignant melanoma, staged as T1BM0N3, with immunohistochemistry results showing Pan-Mel positive and Keratin negative?"
      },
      {
        "from": "gpt",
        "value": "1. Systemic Therapy: Initiate treatment with targeted therapy if mutations such as BRAF V600E or V600K are present (e.g., a combination of BRAF and MEK inhibitors like dabrafenib and trametinib). If no specific mutations are identified, proceed with immune checkpoint inhibitors such as nivolumab or pembrolizumab. 2. Immunotherapy: Consider combination immunotherapy with nivolumab and ipilimumab if the patient can tolerate the potential side effects, as this can provide significant survival benefit in metastatic melanoma. 3. Supportive Care: Provide supportive treatments addressing pain, other symptoms, and psychological aspects to improve the patient\u2019s quality of life."
      }
    ]
  },
  {
    "id": "TCGA-BC-A112-01Z-00-DX1.4CC4A845-25F1-4DC2-8142-9990A66E9C1B-1",
    "image": "TCGA-LIHC/TCGA-BC-A112-01Z-00-DX1.4CC4A845-25F1-4DC2-8142-9990A66E9C1B.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with moderately differentiated hepatocellular carcinoma, staged as T3MXNX, with immunohistochemistry results showing HepPar-1 moderately to strongly positive in a subset, CK7 positive in a subset, CK20 negative, and PSA negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Evaluate for partial hepatectomy if the tumor is resectable and liver function is adequate (Child-Pugh A or early B). Consultation with a surgical oncologist is essential. 2. Liver Transplantation: Consider liver transplantation if the patient meets specific criteria, such as Milan criteria, with limited tumor spread and good liver function. 3. Locoregional Therapies:     - Transarterial chemoembolization (TACE) if the tumor is not resectable but confined to the liver.    - Radiofrequency ablation (RFA) may be appropriate for smaller tumors. 4. Systemic Therapy: Initiate systemic therapy with tyrosine kinase inhibitors like sorafenib or lenvatinib if the tumor is advanced and not amenable to locoregional treatments. 5. Follow-up and Surveillance: Regular monitoring through imaging and serum alpha-fetoprotein (AFP) levels to assess for tumor progression or recurrence."
      }
    ]
  },
  {
    "id": "TCGA-67-6217-01Z-00-DX1.3fa5c69b-60d1-41fb-a86f-48f77d81285f-1",
    "image": "TCGA-LUAD/TCGA-67-6217-01Z-00-DX1.3fa5c69b-60d1-41fb-a86f-48f77d81285f.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with adenocarcinoma, staged as T2aN1M0, with immunohistochemistry results showing Cytokeratin 5/6 positive, Synaptophysin negative, and Chromogranin negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Lobectomy with lymph node dissection is recommended to remove the primary tumor and affected lymph nodes. 2. Adjuvant Chemotherapy: Consider platinum-based chemotherapy (e.g., cisplatin with pemetrexed) to address potential micrometastasis due to N1 staging. 3. Monitoring and Follow-Up: Regular follow-up with imaging and clinical assessments to monitor for recurrence or metastasis."
      }
    ]
  },
  {
    "id": "TCGA-EW-A6SA-01Z-00-DX1.DE032DD7-169D-4AA2-A4E0-1EFC158431FA-1",
    "image": "TCGA-BRCA/TCGA-EW-A6SA-01Z-00-DX1.DE032DD7-169D-4AA2-A4E0-1EFC158431FA.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with ER-positive, PR-negative, HER2-negative poorly differentiated invasive ductal carcinoma, Nottingham grade 3, TNM staging MXT2N0?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Mastectomy or breast-conserving surgery, based on tumor size and breast conservation possibility, with sentinel lymph node biopsy performed. 2. Chemotherapy: Adjuvant chemotherapy is advised due to high grade and tumor size (T2). 3. Endocrine Therapy: Prescribe tamoxifen or aromatase inhibitors for a minimum of 5 years due to ER positivity. 4. Radiation Therapy: Adjuvant radiation therapy should be considered, especially if breast-conserving surgery is performed."
      }
    ]
  },
  {
    "id": "TCGA-3H-AB3L-01Z-00-DX1.AED33A7B-EEED-468B-8892-2B7F338C5471-1",
    "image": "TCGA-MESO/TCGA-3H-AB3L-01Z-00-DX1.AED33A7B-EEED-468B-8892-2B7F338C5471.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with epithelioid malignant mesothelioma, staged as TXM0N2, with immunohistochemistry results showing Keratin 5/6 positive, WWT1 positive, Calretinin positive, and MOC-31 negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Evaluate for possible surgical intervention such as pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP), taking into consideration the patient's overall health and potential benefits of debulking surgery. 2. Chemotherapy: Administer a combination of pemetrexed and cisplatin as first-line chemotherapy to improve survival rates and manage systemic disease. 3. Radiation Therapy: Consider adjuvant radiation therapy, particularly in the mediastinal and nodal regions, to target any residual cancer cells and reduce the risk of local recurrence."
      }
    ]
  },
  {
    "id": "TCGA-AR-A0U4-01Z-00-DX1.DE722DC5-859D-4866-ADCC-ED98EDBFB588-1",
    "image": "TCGA-BRCA/TCGA-AR-A0U4-01Z-00-DX1.DE722DC5-859D-4866-ADCC-ED98EDBFB588.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with triple-negative infiltrating ductal carcinoma, Nottingham grade III, TNM staging T2N0M0?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform a lumpectomy or mastectomy with sentinel lymph node biopsy, considering the tumor size and location. 2. Chemotherapy: Administer adjuvant chemotherapy due to high-grade, triple-negative status, often including anthracycline and taxane-based regimens. 3. Radiation Therapy: Consider post-operative radiation therapy, especially if breast-conserving surgery was chosen, to reduce local recurrence risks."
      }
    ]
  },
  {
    "id": "TCGA-EW-A1P6-01Z-00-DX1.A8024C26-6336-4858-88FD-5679795899BA-1",
    "image": "TCGA-BRCA/TCGA-EW-A1P6-01Z-00-DX1.A8024C26-6336-4858-88FD-5679795899BA.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient with invasive ductal carcinoma, Nottingham grade 2, TNM staging T2N1M0, ER-positive, PR-positive, and HER2-negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform breast-conserving surgery or mastectomy, depending on tumor size and patient preference, followed by sentinel lymph node biopsy or axillary lymph node dissection. 2. Chemotherapy: Consider adjuvant chemotherapy due to nodal involvement and to reduce recurrence risk. 3. Endocrine Therapy: Initiate tamoxifen or an aromatase inhibitor for at least 5 years, given the ER/PR positivity. 4. Radiation Therapy: Advise adjuvant radiation therapy, especially if breast-conserving surgery was performed, to minimize local recurrence risk."
      }
    ]
  },
  {
    "id": "TCGA-CN-6024-01Z-00-DX1.c5791a72-1ded-4723-a33a-68da0685c80b-1",
    "image": "TCGA-HNSC/TCGA-CN-6024-01Z-00-DX1.c5791a72-1ded-4723-a33a-68da0685c80b.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with moderately differentiated squamous cell carcinoma, TNM staging T4aN2M0, with immunohistochemistry results showing p16 negative and HPV negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Consider primary surgical intervention if feasible, such as tumor resection with clear margins, given the locally advanced stage. 2. Chemoradiation: Concurrent chemoradiation is often recommended for T4a lesions with N2 nodal involvement to manage both the primary tumor and regional lymph nodes. Standard regimens include cisplatin-based chemotherapy combined with high-dose radiation therapy. 3. Adjuvant Therapy: Postoperative radiation therapy may be advised to address any remaining microscopic disease, especially for those with close or positive margins after surgery. 4. Multidisciplinary Evaluation: Due to the advanced stage and nodal involvement, a multidisciplinary team should evaluate further individualized treatment options, including possible clinical trials."
      }
    ]
  },
  {
    "id": "TCGA-F7-A624-01Z-00-DX1.5626052F-EA0A-43E0-B011-43276FA282C5-1",
    "image": "TCGA-HNSC/TCGA-F7-A624-01Z-00-DX1.5626052F-EA0A-43E0-B011-43276FA282C5.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with squamous cell carcinoma, TNM staging T2M0NX, with immunohistochemistry results showing Vimentin positive, HMW cytokeratins positive, CK7 positive, S100 negative, HMB45 negative, Chromogranin negative, CD56 negative, and Ki-67 positive in 90%?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform wide local excision with clear margins or consider Mohs micrographic surgery, especially if the tumor is located in a cosmetically sensitive area. 2. Radiation Therapy: Consider adjuvant radiation therapy if surgical margins are positive or if the tumor is not entirely resectable. 3. Chemotherapy: Evaluate for adjuvant or neoadjuvant chemotherapy, given the high Ki-67 index indicating a high proliferation rate. Potential regimens may include cisplatin-based chemotherapy. 4. Follow-up: Implement a rigorous follow-up schedule involving regular physical exams and imaging to monitor for recurrence or metastasis, given the uncertain nodal status (NX)."
      }
    ]
  },
  {
    "id": "TCGA-AO-A0JJ-01Z-00-DX1.D5B636F5-1B47-4033-9938-9DC8CD48CEE9-1",
    "image": "TCGA-BRCA/TCGA-AO-A0JJ-01Z-00-DX1.D5B636F5-1B47-4033-9938-9DC8CD48CEE9.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient with invasive lobular carcinoma, TNM staging T2N1M0, with IHC showing BR-positive, PR-positive, ER-negative, and HER2-negative status?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform mastectomy or breast-conserving surgery with sentinel lymph node biopsy or axillary lymph node dissection, given nodal involvement (N1). 2. Chemotherapy: Adjuvant chemotherapy is recommended due to the nodal involvement and negative ER status. 3. Endocrine Therapy: As BR (and if BR implies a typo or confusion meant for ER, otherwise PR is noted without BR being standard) alone is rare, typically, no endocrine therapy might be suggested if ER is truly negative. Confirm need based on clinical reassessment. 4. Radiation Therapy: Consider adjuvant radiation therapy, particularly if breast-conserving surgery was chosen or in light of nodal involvement."
      }
    ]
  },
  {
    "id": "TCGA-E2-A1LA-01Z-00-DX1.AE49E943-B830-4ED9-B09E-E499441BC2EC-1",
    "image": "TCGA-BRCA/TCGA-E2-A1LA-01Z-00-DX1.AE49E943-B830-4ED9-B09E-E499441BC2EC.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with ER-positive, PR-positive, HER2-negative invasive ductal carcinoma, SBR Grade 2, TNM staging T1cN1M0?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Consider breast-conserving surgery or mastectomy with sentinel lymph node biopsy or axillary lymph node dissection due to nodal involvement. 2. Chemotherapy: Adjuvant chemotherapy is recommended considering the nodal involvement, even though the tumor is small. 3. Endocrine Therapy: Initiate tamoxifen or aromatase inhibitors for at least 5 years because of ER/PR positivity. 4. Radiation Therapy: Adjuvant radiation therapy, especially after breast-conserving surgery to eliminate residual cells and reduce recurrence risk."
      }
    ]
  },
  {
    "id": "TCGA-D8-A13Z-01Z-00-DX1.517140BB-D34C-42F8-952C-340EF16D382F-1",
    "image": "TCGA-BRCA/TCGA-D8-A13Z-01Z-00-DX1.517140BB-D34C-42F8-952C-340EF16D382F.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with invasive ductal carcinoma and mixed invasive carcinoma (ductal, papillary, and cribriform), with TNM staging T2N2M0, and negative for estrogen, progesterone, and HER2 receptors?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Recommend mastectomy or breast-conserving surgery followed by axillary lymph node dissection, due to significant nodal involvement. 2. Chemotherapy: Neoadjuvant or adjuvant chemotherapy is critically recommended because of the triple-negative status and N2 nodal involvement. 3. Radiation Therapy: Adjuvant radiation therapy is advised post-surgery, particularly considering T2 and N2 staging to manage regional recurrence risk."
      }
    ]
  },
  {
    "id": "TCGA-A1-A0SP-01Z-00-DX1.20D689C6-EFA5-4694-BE76-24475A89ACC0-1",
    "image": "TCGA-BRCA/TCGA-A1-A0SP-01Z-00-DX1.20D689C6-EFA5-4694-BE76-24475A89ACC0.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with triple-negative, grade 3 invasive ductal carcinoma, TNM staging T2N0M0?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform breast-conserving surgery (lumpectomy) or mastectomy, depending on patient preference and clinical indications, followed by sentinel lymph node biopsy. 2. Chemotherapy: Administer adjuvant chemotherapy due to the triple-negative status and grade 3 histology. 3. Radiation Therapy: Recommend adjuvant radiation therapy if breast-conserving surgery was performed or depending on surgical margins."
      }
    ]
  },
  {
    "id": "TCGA-BH-A0AU-01Z-00-DX1.E852F218-B15C-4CF8-8FD0-F284043834C4-1",
    "image": "TCGA-BRCA/TCGA-BH-A0AU-01Z-00-DX1.E852F218-B15C-4CF8-8FD0-F284043834C4.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with invasive ductal carcinoma, Nottingham grade 2, with TNM stage T2N0M0 and IHC results showing ER-positive, PR-positive, and HER2/neu equivocal (score 2+)?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Consider breast-conserving surgery or mastectomy, based on patient preference and tumor characteristics, along with sentinel lymph node biopsy. 2. Chemotherapy: Evaluate for adjuvant chemotherapy consideration based on recurrence risk factors and patient health status. 3. Hormonal Therapy: Initiate tamoxifen or aromatase inhibitors for a minimum of 5 years due to ER/PR positivity. 4. HER2-targeted Therapy: Perform FISH testing to further evaluate HER2 status; consider therapy if HER2 positivity is confirmed. 5. Radiation Therapy: Recommend radiation therapy, particularly if breast-conserving surgery is performed, to reduce local recurrence risk."
      }
    ]
  },
  {
    "id": "TCGA-E9-A54Y-01Z-00-DX1.5FD70369-6514-4E5E-8BEF-65DAC5671E1A-1",
    "image": "TCGA-BRCA/TCGA-E9-A54Y-01Z-00-DX1.5FD70369-6514-4E5E-8BEF-65DAC5671E1A.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with infiltrating lobular carcinoma, with TNM staging T2N2M0, ER-positive, PR-positive, HER2-negative, and a Ki-67 index of 6%?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Mastectomy or breast-conserving surgery with axillary lymph node dissection, given the involvement of multiple lymph nodes. 2. Chemotherapy: Adjuvant chemotherapy can be considered due to nodal involvement, although the low Ki-67 index suggests a less aggressive tumor. 3. Endocrine Therapy: Tamoxifen or aromatase inhibitors for at least 5 years, given the strong ER and PR positivity. 4. Radiation Therapy: Adjuvant radiation therapy, especially if breast-conserving surgery was performed or based on nodal involvement."
      }
    ]
  },
  {
    "id": "TCGA-EW-A2FW-01Z-00-DX1.4F948681-81F3-46C5-A4E8-FDE8A4116F7A-1",
    "image": "TCGA-BRCA/TCGA-EW-A2FW-01Z-00-DX1.4F948681-81F3-46C5-A4E8-FDE8A4116F7A.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with poorly differentiated invasive ductal carcinoma, Nottingham grade 3, TNM staging MXT2N0 (I-) with negative keratin IHC in sentinel lymph nodes?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Consider breast-conserving surgery (lumpectomy) or mastectomy based on the tumor size and patient preference, with no need for axillary lymph node dissection due to negative sentinel lymph nodes. 2. Chemotherapy: Adjuvant chemotherapy is recommended given the T2 tumor size and high-grade histology (grade 3). 3. Radiation Therapy: Adjuvant radiation therapy is recommended, especially if breast-conserving surgery is selected, to reduce local recurrence risk. 4. Endocrine Therapy: Initiate treatment with Tamoxifen or aromatase inhibitors if the ER/PR status is determined to be positive."
      }
    ]
  },
  {
    "id": "TCGA-73-4666-01Z-00-DX1.dd9c8922-ddd1-4674-8124-9e334532e47e-1",
    "image": "TCGA-LUAD/TCGA-73-4666-01Z-00-DX1.dd9c8922-ddd1-4674-8124-9e334532e47e.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with poorly differentiated adenocarcinoma, TNM staging T1M1N0, with immunohistochemistry results showing mucin stain positive in tumor cells?"
      },
      {
        "from": "gpt",
        "value": "1. Systemic Therapy: Initiate systemic chemotherapy tailored to adenocarcinoma, such as a platinum-based regimen (e.g., cisplatin or carboplatin combined with another agent like pemetrexed or a taxane) due to the presence of metastasis (M1). 2. Targeted Therapy: Consider molecular profiling to identify potential actionable mutations (e.g., EGFR, ALK, ROS1) that could benefit from targeted therapy. 3. Palliative Care: Implement palliative care measures to manage symptoms and improve quality of life, given the metastatic nature of the disease. 4. Clinical Trials: Evaluate the patient's eligibility for clinical trials that may provide access to new and emerging therapies."
      }
    ]
  },
  {
    "id": "TCGA-D8-A1JB-01Z-00-DX1.6CF48257-066C-4B8C-91AA-30A6B4AD4307-1",
    "image": "TCGA-BRCA/TCGA-D8-A1JB-01Z-00-DX1.6CF48257-066C-4B8C-91AA-30A6B4AD4307.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with ER-positive, PR-positive, HER2-negative invasive ductal carcinoma and ductal carcinoma in situ, Nottingham grade 2, with TNM staging T2N1M0?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Mastectomy or breast-conserving surgery with axillary lymph node dissection, considering nodal involvement. 2. Chemotherapy: Adjuvant chemotherapy may be recommended due to nodal involvement and T2 stage. 3. Endocrine Therapy: Initiate Tamoxifen or aromatase inhibitors for at least 5 years due to ER and PR positivity. 4. Radiation Therapy: Include adjuvant radiation therapy, especially if breast-conserving surgery is performed or based on nodal involvement."
      }
    ]
  },
  {
    "id": "TCGA-A2-A25D-01Z-00-DX1.41DADDB8-3E3F-4F8F-8BE7-C43F8FBCFD2B-1",
    "image": "TCGA-BRCA/TCGA-A2-A25D-01Z-00-DX1.41DADDB8-3E3F-4F8F-8BE7-C43F8FBCFD2B.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient with invasive lobular carcinoma, pleomorphic type, poorly differentiated, Nottingham Grade 3, TNM staging T2N3A, ER-positive, PR-negative, and HER2-negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Consider modified radical mastectomy due to extensive nodal involvement, along with axillary lymph node dissection. 2. Chemotherapy: Adjuvant chemotherapy is recommended because of high-grade histology and significant nodal involvement. 3. Endocrine Therapy: Initiate tamoxifen or aromatase inhibitors for at least 5 to 10 years due to strong ER positivity. 4. Radiation Therapy: Adjuvant radiation therapy to the chest wall and regional lymph nodes, considering T2N3A staging."
      }
    ]
  },
  {
    "id": "TCGA-BC-A69H-01Z-00-DX1.22CA7EA4-B8EC-444C-90AA-33095CC53585-1",
    "image": "TCGA-LIHC/TCGA-BC-A69H-01Z-00-DX1.22CA7EA4-B8EC-444C-90AA-33095CC53585.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with poorly differentiated carcinoma, favoring hepatocellular carcinoma, with TNM staging T2M0NX, and immunohistochemistry results showing Cytokeratin AE1/AE3 positive, CK8/18 positive, HepPar1 positive, MOC-31 patchy moderate staining, and CD10 negative?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Assess for liver resection or liver transplantation, considering the tumor size (T2) and absence of metastasis (M0). Evaluate liver function and overall patient health to determine suitability. 2. Locoregional Therapy: Consider transarterial chemoembolization (TACE) or radiofrequency ablation (RFA) to target localized liver tumors if surgery is not an option. 3. Systemic Therapy: Initiate systemic therapy with agents like sorafenib or lenvatinib, particularly if surgery or locoregional therapies are not feasible or in a neoadjuvant setting. 4. Follow-Up and Monitoring: Regular imaging and serum alpha-fetoprotein (AFP) levels monitoring post-treatment to detect any recurrence or progression."
      }
    ]
  },
  {
    "id": "TCGA-BH-A5IZ-01Z-00-DX1.6C871030-82E1-463E-A67B-976A5F3DCDB2-1",
    "image": "TCGA-BRCA/TCGA-BH-A5IZ-01Z-00-DX1.6C871030-82E1-463E-A67B-976A5F3DCDB2.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with ER-positive, PR-negative, HER2-negative invasive ductal carcinoma, TNM staging CM0 (I+) T2N1A?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Options include mastectomy or breast-conserving surgery, depending on tumor characteristics and patient preference, followed by sentinel lymph node biopsy or axillary dissection. 2. Chemotherapy: Adjuvant chemotherapy may be considered due to nodal involvement (N1A). 3. Endocrine Therapy: Initiate tamoxifen or aromatase inhibitors for at least 5 years, as the tumor is estrogen receptor-positive. 4. Radiation Therapy: Recommended, particularly if breast-conserving surgery is selected or in the presence of significant nodal involvement."
      }
    ]
  },
  {
    "id": "TCGA-BH-A0BZ-01Z-00-DX1.45EB3E93-A871-49C6-9EAE-90D98AE01913-1",
    "image": "TCGA-BRCA/TCGA-BH-A0BZ-01Z-00-DX1.45EB3E93-A871-49C6-9EAE-90D98AE01913.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient with infiltrating ductal carcinoma, Nottingham Grade 3, staging M0T3N1a, and ER-positive, PR-positive, HER2-negative IHC findings?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform a mastectomy or breast-conserving surgery, along with axillary lymph node dissection. 2. Chemotherapy: Administer adjuvant chemotherapy due to grade 3 tumor histology and nodal involvement. 3. Endocrine Therapy: Prescribe Tamoxifen or aromatase inhibitors for a minimum of 5 years, given ER/PR positivity. 4. Radiation Therapy: Consider adjuvant radiation therapy, especially if breast-conserving surgery is selected or if there is significant nodal involvement."
      }
    ]
  },
  {
    "id": "TCGA-FR-A8YC-06Z-00-DX1.C74DAE48-0901-4858-A47B-CAF5ED89C5D0-1",
    "image": "TCGA-SKCM/TCGA-FR-A8YC-06Z-00-DX1.C74DAE48-0901-4858-A47B-CAF5ED89C5D0.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with metastatic melanoma, TNM staging T3BM0N0, with immunohistochemistry results showing MART-1 positive and HMB-45 positive?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Evaluate for surgical removal of metastatic sites if applicable, primarily for symptom control or limited metastases. 2. Systemic Therapy: Consider first-line systemic therapies such as immune checkpoint inhibitors (e.g., pembrolizumab or nivolumab) or targeted therapies (e.g., BRAF and MEK inhibitors if there is a BRAF mutation). 3. Radiation Therapy: Utilize for palliation of symptoms or for control of specific metastatic sites, if necessary. 4. Clinical Trials: Encourage participation in clinical trials exploring novel therapies or combinations for metastatic melanoma."
      }
    ]
  },
  {
    "id": "TCGA-EE-A2MM-01Z-00-DX1.8EBF6AD7-6812-4779-932A-665F898E18AA-1",
    "image": "TCGA-SKCM/TCGA-EE-A2MM-01Z-00-DX1.8EBF6AD7-6812-4779-932A-665F898E18AA.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with metastatic malignant melanoma, staged as T2N0M0, with immunohistochemistry results showing S100 positivity, Melan-A positivity, and HMB45 negativity?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Wide local excision of the primary tumor with appropriate margins. 2. Sentinel Lymph Node Biopsy: Given that it is T2, to evaluate for microscopic nodal involvement, despite clinical N0 status. 3. Adjuvant Therapy: Consider adjuvant immunotherapy such as nivolumab or pembrolizumab, to reduce the risk of recurrence. 4. Follow-up and Monitoring: Regular dermatologic examinations and imaging studies as per melanoma follow-up guidelines to monitor for recurrence or metastasis."
      }
    ]
  },
  {
    "id": "TCGA-E2-A15G-01Z-00-DX1.BAA5235E-1022-463B-A852-586ED7CA75FF-1",
    "image": "TCGA-BRCA/TCGA-E2-A15G-01Z-00-DX1.BAA5235E-1022-463B-A852-586ED7CA75FF.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with invasive mixed (ductal/lobular) carcinoma, SBR Grade 1, TNM stage T2N0M0, with ER-positive, PR-positive, and HER2-negative status?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Consider breast-conserving surgery (lumpectomy) or mastectomy depending on the patient\u2019s preference and tumor characteristics, with sentinel lymph node biopsy due to potential occult nodal involvement. 2. Endocrine Therapy: Administer tamoxifen or aromatase inhibitors for at least 5 years given the ER and PR positivity. 3. Radiation Therapy: Recommend adjuvant radiation therapy to the breast following breast-conserving surgery to reduce local recurrence risk. 4. Chemotherapy: Generally not indicated primarily due to favorable SBR Grade 1, and absence of nodal or distant metastasis, though patient-specific factors should be assessed."
      }
    ]
  },
  {
    "id": "TCGA-E2-A14W-01Z-00-DX1.2AF665A9-F582-4C41-B2B8-1982648CDEC7-1",
    "image": "TCGA-BRCA/TCGA-E2-A14W-01Z-00-DX1.2AF665A9-F582-4C41-B2B8-1982648CDEC7.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with ER-positive, PR-positive, HER2-positive invasive ductal carcinoma, poorly differentiated, TNM staging T2N0M0?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Breast-conserving surgery or mastectomy based on tumor size and patient preference, followed by sentinel lymph node biopsy. 2. Chemotherapy: Adjuvant chemotherapy is recommended, given the aggressive nature and HER2 positivity. 3. HER2-targeted Therapy: Include trastuzumab (Herceptin) with chemotherapy, followed by maintenance therapy for 1 year. 4. Endocrine Therapy: Initiate endocrine therapy such as tamoxifen or aromatase inhibitors for at least 5 years due to ER/PR positivity. 5. Radiation Therapy: Offer post-operative radiation therapy, especially if breast-conserving surgery was performed."
      }
    ]
  },
  {
    "id": "TCGA-EM-A3FL-01Z-00-DX1.8B0828AC-4EFF-4C9A-8B11-B249C97C6F59-1",
    "image": "TCGA-THCA/TCGA-EM-A3FL-01Z-00-DX1.8B0828AC-4EFF-4C9A-8B11-B249C97C6F59.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with multifocal papillary carcinoma, follicular variant, with TNM staging T1BMXNX and immunohistochemistry results showing Galectin-3 negative, Cytokeratin 19 focally positive, and HBME-1 few cells positive with an apical and membranous pattern?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Recommend total thyroidectomy due to the multifocal nature of the tumor. 2. Radioactive Iodine Therapy: Consider post-surgical radioactive iodine (RAI) therapy to ablate any remaining thyroid tissue and target potential micrometastases, given the multifocality. 3. Thyroid Hormone Suppression Therapy: Begin levothyroxine to suppress TSH and reduce the risk of recurrence."
      }
    ]
  },
  {
    "id": "TCGA-ZP-A9D4-01Z-00-DX1.306ADF14-E71A-4E44-BF28-F7733A1937EC-1",
    "image": "TCGA-LIHC/TCGA-ZP-A9D4-01Z-00-DX1.306ADF14-E71A-4E44-BF28-F7733A1937EC.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with well-differentiated hepatocellular carcinoma, TNM staging T1MXNX, with immunohistochemistry results showing Glypican-3 focally positive?"
      },
      {
        "from": "gpt",
        "value": "1. Surgical Treatment: Consider partial hepatectomy as the first-line treatment, given the early-stage (T1) diagnosis if the patient has adequate liver function. 2. Ablation Therapy: For patients who are not surgical candidates, ablative therapies such as radiofrequency ablation (RFA) or microwave ablation (MWA) can be effective. 3. Surveillance: Regular follow-up with imaging (e.g., MRI/CT) and serum alpha-fetoprotein (AFP) levels every 3-6 months to monitor for recurrence or progression. 4. Liver Transplantation: Evaluate for liver transplantation in appropriate candidates, especially if additional underlying liver disease is present."
      }
    ]
  },
  {
    "id": "TCGA-AR-A1AN-01Z-00-DX1.1118F9FE-6DF2-4496-B102-D3A10D332EC0-1",
    "image": "TCGA-BRCA/TCGA-AR-A1AN-01Z-00-DX1.1118F9FE-6DF2-4496-B102-D3A10D332EC0.pt",
    "conversations": [
      {
        "from": "human",
        "value": "<image>\nWhat is the recommended treatment plan for a patient diagnosed with infiltrating ductal carcinoma, Nottingham grade II, TNM staging T2N0M0, and pending HER2 IHC results?"
      },
      {
        "from": "gpt",
        "value": "1. Surgery: Perform breast-conserving surgery (lumpectomy) or mastectomy based on tumor characteristics and patient preference, along with sentinel lymph node biopsy. 2. Radiation Therapy: Consider adjuvant radiation therapy if breast-conserving surgery is performed. 3. Endocrine Therapy: If further testing indicates ER or PR positivity, prescribe tamoxifen or aromatase inhibitors for at least 5 years. 4. Chemotherapy: Pending HER2 results, consider adjuvant chemotherapy if further pathological risk factors are identified. 5. HER2-targeted Therapy: If HER2 positivity is confirmed, consider the addition of trastuzumab (Herceptin) with chemotherapy for HER2-targeted treatment."
      }
    ]
  }
]